Blog

Specialty pharmacists can help patients changing payers or providers, and specialty pharmacy data helps with medication adherence strategies.

Specialty pharmacy distribution is changing as specialty drug treatments become more commonplace. Many biosimilars have entered the rare disease market, directly competing with biologics like Humira that represented breakthroughs in their time. New treatments for a wide range of conditions are also available, including biologics, cell and gene therapies for rare diseases.  Wider adoption of

Patients readily switch doctors, making medication adherence strategies difficult. Specialty pharmacy data can assist with the patient journey orchestration.

Specialty pharmacists can help patients changing payers or providers, and specialty pharmacy data helps with medication adherence strategies.

A look at pharma market insights plus regulatory news updates from the FDA and related agencies to wrap up 2023.

Marketwide benchmarking and pharma brand benchmarking provide two key perspectives on how a rare disease treatment performs.

Cell and gene therapies in development today provide real world evidence analytics for how rare diseases will be treated tomorrow.

Competing Humira biosimilars are already on the market. Examining them provides pharma market insights such as specialty pharmacy trends and a go-to-market strategy.

Specialty pharmacy data from patient journey orchestration and specialty pharmacy analytics helps specialty pharmacies outperform competitors.